Trials like the dostarlimab study in rectal cancer and NICHE in colon cancer show neoadjuvant immunotherapy can induce profound responses in MSI-high tumors. This is creating a new paradigm where major surgery might be avoided entirely for some patients, marking a significant shift in treatment strategy.

While neoadjuvant immunotherapy shows astounding success in MSI-high rectal cancer, the primary difficulty for clinicians lies in accurately assessing complete response via endoscopy and MRI, and managing unique complications like mucin pools or stenosis, rather than simply administering the treatment.

Unlike the 100% complete clinical response seen in some rectal cancer trials, studies like NICHE-2 for MSI-high colon cancer show a lower pathologic complete response rate (around 68%). This crucial difference suggests non-operative management is far riskier in colon cancer and requires a distinct clinical approach.

In a study of neoadjuvant Dostarlamab for MSI-high tumors, 100% of rectal cancer patients achieved a clinical complete response, compared to 82% of colon cancer patients. Experts find this high degree of discordance surprising and currently lack a clear biological explanation, as such differences are not typically observed in the metastatic setting.

Unlike rectal cancer where MRI aids response assessment, MSI-high colon cancer lacks a reliable imaging modality to confirm a pathologic complete response after neoadjuvant immunotherapy. This makes a "watch and wait" approach far more challenging and not currently recommended outside of a clinical trial.

While immunotherapy is largely ineffective in metastatic microsatellite stable (MSS) colorectal cancer, emerging data suggests it may have surprising efficacy in the early-stage (neoadjuvant) setting. This differential response is likely due to a more favorable tumor microenvironment in earlier disease, suggesting a new therapeutic window.

Retrospective data suggests patients with MSI-high rectal cancer might not just respond poorly to standard neoadjuvant chemoradiation (TNT), but their disease could actually progress. This makes immunotherapy a potentially safer and more effective first-line neoadjuvant choice, not just an alternative.

Analysis across multiple studies suggests that longer treatment durations with neoadjuvant immunotherapy, up to six months, are associated with higher rates of complete pathologic response in localized MSI-high colorectal cancer. This indicates that treatment duration is a critical variable for optimizing patient outcomes and designing future trials.

Patients showing a near-complete response at the end of a six-month immunotherapy course may still convert to a full complete response two months later without additional treatment. Clinicians should consider 'holding their nerve' and re-evaluating with repeat imaging before altering the treatment plan.